DK2364983T3 - Nyt tricyklisk derivat eller farmaceutisk acceptable salte deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende disse - Google Patents
Nyt tricyklisk derivat eller farmaceutisk acceptable salte deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende disseInfo
- Publication number
- DK2364983T3 DK2364983T3 DK09826270.2T DK09826270T DK2364983T3 DK 2364983 T3 DK2364983 T3 DK 2364983T3 DK 09826270 T DK09826270 T DK 09826270T DK 2364983 T3 DK2364983 T3 DK 2364983T3
- Authority
- DK
- Denmark
- Prior art keywords
- acceptable salts
- composition containing
- tricyclic derivative
- pharmaceutical composition
- preparing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 4
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 4
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20080111808 | 2008-11-11 | ||
| PCT/KR2009/006618 WO2010056038A2 (ko) | 2008-11-11 | 2009-11-11 | 신규한 트리시클릭 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2364983T3 true DK2364983T3 (da) | 2013-12-09 |
Family
ID=42170514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09826270.2T DK2364983T3 (da) | 2008-11-11 | 2009-11-11 | Nyt tricyklisk derivat eller farmaceutisk acceptable salte deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende disse |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8815891B2 (da) |
| EP (1) | EP2364983B1 (da) |
| JP (1) | JP5403709B2 (da) |
| KR (1) | KR100968175B1 (da) |
| CN (1) | CN102245612B (da) |
| AU (1) | AU2009314760B2 (da) |
| BR (1) | BRPI0915273B1 (da) |
| CA (1) | CA2743257C (da) |
| DK (1) | DK2364983T3 (da) |
| ES (1) | ES2443127T3 (da) |
| MX (1) | MX2011004957A (da) |
| PL (1) | PL2364983T3 (da) |
| PT (1) | PT2364983E (da) |
| RU (1) | RU2470934C1 (da) |
| WO (1) | WO2010056038A2 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101827444B1 (ko) * | 2012-02-01 | 2018-02-08 | 제일약품주식회사 | 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법 |
| WO2015089842A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Novel tricyclic calcium sensing receptor antagonists for the treatment of osteoporosis |
| US20150320706A1 (en) | 2014-05-12 | 2015-11-12 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| JP6668362B2 (ja) | 2015-02-02 | 2020-03-18 | フォーマ セラピューティクス，インコーポレイテッド | Ｈｄａｃ阻害薬としての３−アルキル−４−アミド−二環式［４，５，０］ヒドロキサム酸 |
| US10183934B2 (en) | 2015-02-02 | 2019-01-22 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors |
| CN107849040B (zh) * | 2015-06-09 | 2021-04-06 | 肿瘤学治疗公司 | 三环衍生化合物、其制备方法、和含有其的药物组合物 |
| KR101775356B1 (ko) | 2015-07-06 | 2017-09-06 | 재단법인 아산사회복지재단 | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 |
| RU2602503C1 (ru) * | 2015-09-23 | 2016-11-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА) | Трициклические соединения, обладающие противобактериальной активностью, способ их получения и содержащее их фармацевтическое средство |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| KR20180062804A (ko) * | 2016-12-01 | 2018-06-11 | 사회복지법인 삼성생명공익재단 | 트리시클릭 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 허혈성 급성 신손상 예방 또는 치료용 약학적 조성물 |
| EP3558971B1 (en) | 2016-12-22 | 2022-02-23 | Global Blood Therapeutics, Inc. | Histone methyltransferase inhibitors |
| CN110997671A (zh) | 2017-06-09 | 2020-04-10 | 全球血液疗法股份有限公司 | 作为组蛋白甲基转移酶抑制剂的氮杂吲哚化合物 |
| AU2019253510B2 (en) * | 2018-04-13 | 2023-08-10 | Cancer Research Technology Limited | BCL6 inhibitors |
| WO2020072675A1 (en) | 2018-10-02 | 2020-04-09 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c) |
| WO2020155141A1 (zh) * | 2019-02-02 | 2020-08-06 | 中国科学院上海有机化学研究所 | 治疗神经退行性疾病或rna结合蛋白发生异常导致的疾病的药物组合物及其应用 |
| KR20210014024A (ko) | 2019-07-29 | 2021-02-08 | 제일약품주식회사 | 트리사이클릭 유도체를 이용한 뇌졸중의 치료 방법 |
| CA3146528A1 (en) * | 2019-07-29 | 2021-02-04 | Jeil Pharmaceutical Co.,Ltd | Method for treating stroke by using tricyclic derivative |
| KR20220149268A (ko) * | 2021-04-30 | 2022-11-08 | 주식회사 온코크로스 | 트리사이클로 유도체 화합물을 포함하는 대사질환 예방 또는 치료용 조성물 |
| CN115554303B (zh) * | 2021-09-18 | 2024-07-09 | 上海科技大学 | 一种三环类化合物、其制备方法及其应用 |
| WO2023061406A1 (zh) * | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| WO2024258904A1 (en) * | 2023-06-13 | 2024-12-19 | University Of Georgia Research Foundation, Inc. | Tetrahydroacridinone analogues for treatment and prevention of malaria |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391554A (en) * | 1992-09-09 | 1995-02-21 | Warner-Lambert Company | Dihydro- and tetrahydronaphthyridines |
| US6197785B1 (en) * | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| JP2000239273A (ja) | 1999-02-16 | 2000-09-05 | Nippon Kayaku Co Ltd | ４−アミノ−５，６，７，８−テトラヒドロ〔１，６〕ナフチリジン誘導体の新規製造法 |
| TWI262919B (en) * | 1999-10-25 | 2006-10-01 | Yamanouchi Pharma Co Ltd | Naphthyridine derivative |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| HRP20050375B1 (hr) * | 2002-09-30 | 2014-03-14 | Bayer Intellectual Property Gmbh | Taljeni azol-pirimidin derivati |
| DE102004028973A1 (de) * | 2004-06-16 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| CN101421268B (zh) * | 2006-02-15 | 2016-01-06 | Abbvie公司 | 作为有效parp抑制剂的吡唑并喹诺酮 |
| MX2009002298A (es) * | 2006-09-01 | 2009-06-04 | Cylene Pharmaceuticals Inc | Moduladores de serina-treonina proteina quinasa y de parp. |
| KR101179753B1 (ko) | 2007-11-06 | 2012-09-04 | 제일약품주식회사 | 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물 |
-
2009
- 2009-11-11 AU AU2009314760A patent/AU2009314760B2/en active Active
- 2009-11-11 WO PCT/KR2009/006618 patent/WO2010056038A2/ko not_active Ceased
- 2009-11-11 PT PT98262702T patent/PT2364983E/pt unknown
- 2009-11-11 CA CA2743257A patent/CA2743257C/en active Active
- 2009-11-11 BR BRPI0915273-3A patent/BRPI0915273B1/pt active IP Right Grant
- 2009-11-11 KR KR1020090108588A patent/KR100968175B1/ko active Active
- 2009-11-11 CN CN200980150285.4A patent/CN102245612B/zh active Active
- 2009-11-11 RU RU2011123799/04A patent/RU2470934C1/ru active
- 2009-11-11 PL PL09826270T patent/PL2364983T3/pl unknown
- 2009-11-11 ES ES09826270.2T patent/ES2443127T3/es active Active
- 2009-11-11 MX MX2011004957A patent/MX2011004957A/es active IP Right Grant
- 2009-11-11 US US13/128,030 patent/US8815891B2/en active Active
- 2009-11-11 DK DK09826270.2T patent/DK2364983T3/da active
- 2009-11-11 EP EP09826270.2A patent/EP2364983B1/en active Active
- 2009-11-11 JP JP2011536240A patent/JP5403709B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2470934C1 (ru) | 2012-12-27 |
| EP2364983A2 (en) | 2011-09-14 |
| CA2743257A1 (en) | 2010-05-20 |
| US8815891B2 (en) | 2014-08-26 |
| BRPI0915273A2 (pt) | 2015-08-04 |
| KR100968175B1 (ko) | 2010-07-07 |
| HK1164292A1 (en) | 2012-09-21 |
| CN102245612A (zh) | 2011-11-16 |
| US20110218193A1 (en) | 2011-09-08 |
| AU2009314760A1 (en) | 2011-06-30 |
| PT2364983E (pt) | 2014-01-07 |
| KR20100053468A (ko) | 2010-05-20 |
| AU2009314760B2 (en) | 2011-11-10 |
| PL2364983T3 (pl) | 2014-04-30 |
| ES2443127T3 (es) | 2014-02-17 |
| EP2364983A4 (en) | 2012-05-09 |
| CA2743257C (en) | 2014-02-11 |
| BRPI0915273B1 (pt) | 2021-08-03 |
| JP5403709B2 (ja) | 2014-01-29 |
| CN102245612B (zh) | 2014-11-05 |
| JP2012508273A (ja) | 2012-04-05 |
| EP2364983B1 (en) | 2013-10-23 |
| WO2010056038A2 (ko) | 2010-05-20 |
| MX2011004957A (es) | 2011-08-12 |
| WO2010056038A3 (ko) | 2010-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2364983T3 (da) | Nyt tricyklisk derivat eller farmaceutisk acceptable salte deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende disse | |
| EA201070328A1 (ru) | Соединения триазолопиридина и их применение в качестве ингибиторов ask | |
| EA201690520A1 (ru) | Способ получения замещенных 5-фтор-1h-пиразолопиридинов | |
| NZ738187A (en) | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | |
| MX2010009752A (es) | Compuestos de oxadiazoantraceno para el tratamiento de diabetes. | |
| WO2008001195A3 (en) | Novel processes for the preparation of dpp iv inhibitors | |
| NO20093009L (no) | Kondensert ring heterocykel kinase modulatorer | |
| WO2011132051A3 (en) | Tricycle compounds as phosphodiesterase-10 inhibitors | |
| BR112012021771A2 (pt) | métodos de uso de inibidores de contransportadores de sódio-glicose 1 e 2. | |
| WO2010147898A3 (en) | Small molecule inhibitors of spleen tyrosine kinase (syk) | |
| WO2009151598A8 (en) | Diazacarbazoles and methods of use | |
| WO2010083207A3 (en) | Protein kinase c inhibitors and uses thereof | |
| PL2247602T3 (pl) | Pochodne O-glukuronido-adamantylowe jako inhibitory dipeptydylopeptydazy IV do leczenia cukrzycy | |
| WO2011147951A8 (en) | Cycloamino derivatives as gpr119 agonists | |
| MX2009008425A (es) | Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9. | |
| GEP201706707B (en) | 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | |
| HK1207860A1 (en) | 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders | |
| MY164354A (en) | Asymmetric ureas and medical uses thereof | |
| WO2010129918A8 (en) | Triptolide prodrugs | |
| WO2010134025A3 (en) | Oral compositions of celecoxib | |
| MX2012006822A (es) | 1,7-diazacarbazoles y metodos de uso. | |
| MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
| IN2012DN03846A (da) | ||
| MX2010009147A (es) | Derivados de pirrolidinilo y usos de los mismos. | |
| GB201114389D0 (en) | Novel compounds |